Novartis (NVS) Expected to Announce Earnings on Friday

Novartis (NYSE:NVS - Get Free Report) is expected to be posting its quarterly earnings results before the market opens on Friday, January 31st. Analysts expect Novartis to post earnings of $1.80 per share and revenue of $12.86 billion for the quarter. Investors that wish to listen to the company's conference call can do so using this link.

Novartis (NYSE:NVS - Get Free Report) last announced its quarterly earnings results on Tuesday, October 29th. The company reported $2.06 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.94 by $0.12. Novartis had a net margin of 35.96% and a return on equity of 34.80%. The firm had revenue of $12.82 billion during the quarter, compared to analysts' expectations of $12.62 billion. During the same period in the prior year, the company posted $1.74 EPS. On average, analysts expect Novartis to post $8 EPS for the current fiscal year and $8 EPS for the next fiscal year.

Novartis Trading Up 1.2 %

Shares of NVS stock traded up $1.25 during mid-day trading on Wednesday, hitting $103.09. The company's stock had a trading volume of 2,374,460 shares, compared to its average volume of 1,730,577. The company has a market cap of $210.72 billion, a PE ratio of 11.97, a P/E/G ratio of 1.42 and a beta of 0.57. The company's fifty day simple moving average is $100.07 and its 200-day simple moving average is $108.57. The company has a debt-to-equity ratio of 0.55, a quick ratio of 0.90 and a current ratio of 1.11. Novartis has a 52 week low of $92.35 and a 52 week high of $120.92.

Wall Street Analysts Forecast Growth

Several analysts have recently commented on the company. Erste Group Bank reissued a "hold" rating on shares of Novartis in a research note on Tuesday, November 19th. BMO Capital Markets raised their price target on shares of Novartis from $118.00 to $120.00 and gave the stock a "market perform" rating in a research note on Wednesday, October 30th. Finally, HSBC downgraded shares of Novartis from a "hold" rating to a "reduce" rating in a research note on Wednesday, December 4th. Two equities research analysts have rated the stock with a sell rating and six have issued a hold rating to the company. According to data from MarketBeat, the stock has an average rating of "Hold" and a consensus target price of $123.38.

Novartis Company Profile

Novartis AG engages in the research, development, manufacture, and marketing of healthcare products in Switzerland and internationally. The company offers prescription medicines for patients and physicians. It focuses on therapeutic areas, such as cardiovascular, renal and metabolic, immunology, neuroscience, and oncology, as well as ophthalmology and hematology.